CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


GX-19Wiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (2)


Name (Synonyms) Correlation
drug1077 Human biological samples Wiki 1.00
drug2176 Saline Wiki 0.38

Correlated MeSH Terms (4)


Name (Synonyms) Correlation
D003141 Communicable Diseases NIH 0.09
D007239 Infection NIH 0.06
D045169 Severe Acute Respiratory Syndrome NIH 0.05
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 A Phase 1/2a, Multi-center, Randomized, Double-blind, Placebo-controlled Study to Investigate the Safety, Tolerability, and Immunogenicity of GX-19, a COVID-19 Preventive DNA Vaccine in Healthy Subjects

The objective of our study is to evaluate safety, tolerability, and immunogenicity of COVID-19 preventive DNA vaccine in healthy volunteers.

NCT04445389 SARS-CoV-2 Drug: GX-19 Drug: Saline

Primary Outcomes

Description: solicited local and systemic AEs after vaccination

Measure: Incidence of solicited adverse events

Time: Through 1 year post vaccination

Description: unsolicited AEs after vaccination

Measure: Incidence of unsolicited adverse events

Time: Through 1 year post vaccination

Description: percentage of subjects with SAEs

Measure: Incidence of serious adverse events

Time: Through 1 year post vaccination

Secondary Outcomes

Description: Change from baseline in antigen-specific binding antibody titers

Measure: Geometric mean titer (GMT) of antigen-specific binding antibody titers

Time: Through 1 year post vaccination

Description: Seroconversion rate can be calculated based on test results reaching the quantifiable antibody level after vaccination

Measure: Percentage of subjects who seroconverted after vaccination

Time: Through 1 year post vaccination

Description: NAb is regarded as produced when FRNT50 is detected more than four times the baseline after vaccination

Measure: Geometric mean titer (GMT) of neutralizing antibody level

Time: Through 1 year post vaccination

Description: Change from baseline in antigen-specific binding antibody titers

Measure: Geometric mean fold rise (GMFR) of antigen-specific binding antibody titers

Time: Through 1 year post vaccination

Other Outcomes

Description: Antigen-specific IFN-γ T cell immune response assessed before/after vaccination

Measure: Change from baseline in antigen-specific IFN-g cellular immune response

Time: Through 1 year post vaccination


No related HPO nodes (Using clinical trials)